Antimicrobial compounds were isolated from the secondary metabolites of Gordonia, a resident of intestinal tract of Periplaneta americana

Yan Ma
Guangdong Pharmaceutical University  https://orcid.org/0000-0002-0498-7565

Minhua Xu
Guangdong Pharmaceutical University

Hancong Liu
Guangdong Pharmaceutical University

Tiantian Yu
Guangdong Pharmaceutical University

Ping Guo
Guangdong Pharmaceutical University

Wenbin Liu
Guangdong Pharmaceutical University

Xiaobao Jin (✉ jinxf2001@163.com)
Guangdong Pharmaceutical University

Original article

Keywords: Gordonia, Secondary metabolites, Antimicrobial activity, Antiproliferative activity, Periplaneta americana.

DOI: https://doi.org/10.21203/rs.3.rs-604184/v1

License: ©️  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Microbial secondary metabolites are one of the main sources of bioactive natural products. It is estimated that around 75% of all antibiotics are derived from secondary metabolites produced by filamentous actinomycete. *Gordonia* sp. are members of the actinomycete family, their contribution to the environment improvement and environmental protection by their biological degradation ability, but there are few studies on the antimicrobial activity of their secondary metabolites. Our team isolated a *Gordonia* strain WA 4–31 with anti-*Candida albicans* activity from the intestinal tract of *Periplaneta americana* in the early stage. In this study, we firstly identified the strain WA 4–31 by the morphological characteristics and the phylogenetic analyses, and found that it homologous to a strain of *Gordonia* from the Indian desert by 100%. Then four compounds, Actinomycin D (1), Actinomycin X₂ (2), Mojavensin A (3) and cyclic (leucine-leucne) dipeptide (4) were purified from the ethyl acetate extract of the fermented broth of the strain. The compounds 1–4 had activities against *Candida albicans*, *Aspergillus niger*, *Aspergillus fumigatus* and *Trichophyton rubrum*. They also had activities against methicillin-resistant *Staphylococcus aureus* (MRSA) and *Escherichia coli*. Besides, compounds 1–3 had varying degrees of antiproliferative activity on CNE-2 cells and HepG-2 cells. These indicated that *Gordonia* rare actinomycete from the intestinal tract of *Periplaneta americana* possessed a potential as a source of active secondary metabolites.

Introduction

Microbial secondary metabolites are one of the main sources of bioactive natural products and are also one of the main sources of drugs. It is estimated that around 75% of all antibiotics are derived from secondary metabolites produced by filamentous actinomycete, especially *Streptomyces* species. But over time, the continual rediscovery of known compounds from secondary metabolites of actinobacteria has resulted. Consequently, special extreme environment and growing conditions for bacteria and Fungi raised much concerns in recent years (Sayed AM et al. 2020), such as deep-sea environment, with characteristic features of high salinity, high pressure, low temperature and low nutrition (Sivalingam P et al. 2019; Zain Ul et al. 2019); cold polar regions (Durán P et al. 2019); deserts (Velez P et al. 2018; Riahi K et al. 2019) or endogenous environment in insects and plants. (Torres-Mendoza D et al. 2020; Xu X et al. 2020).

Endogenous microorganisms of insects and plants have attracted much attention in recent years. They play important role of acting as reservoirs of novel bioactive secondary metabolites that serve as a potential candidate for antimicrobial, anti-insect, anticancer and many more properties (Tanvir R et al. 2017). In order to cope with the emergence of drug resistance, scientific efforts have been aimed at the bioprospecting of microorganisms’ secondary metabolites, with special emphasis on the search for antimicrobial natural products derived from endophytes (Kaur N and Arora DS. 2020; Mastan A et al. 2020; Martinez-Klimova E et al. 2017; Silva FA et al. 2018). Besides, in the existing research reports of insect microorganisms, most of them focus on pest control, biological agents, ecological protection and ecological diversity, and the study on antimicrobial activity of their secondary metabolites is less (Dantur KI et al. 2015; Guo et al. 2017; Zheng Y et al. 2020). Our previous study showed that the endobacteria in the intestinal tract of *Periplaneta americana* exhibited various antimicrobial activities against all tested pathogens (Fang X et al. 2018; Chen Z et al. 2020).

Rare actinomycetes have attracted more attention with a hope to discover new antibiotics. At present, some antibiotics that have been used in clinic, such as gentamicin, erythromycin, vancomycin and rifampicin, are all
from rare actinomycetes (Abidi S et al. 2020). Rare actinomycete Gordonia are usually used for the environment improvement and environmental protection by its biological degradation ability, but there are few studies on its antimicrobial activity (Shintani M et al. 2019). Our team isolated a Gordonia strain WA 4-31 with anti-Candida albicans activity from the intestinal tract of Periplaneta americana. In this study, four compounds were isolated and purified from the ethyl acetate extract of fermentation broth of the Gordonia strain WA 4-31 with antimicrobial activity, especially compounds 1-3 Actinomycin D (1), Actinomycin X₂ (2), Mojavensin A (3) showed better anti-fungal and anti-cancer activities. The study reported the antimicrobial compounds isolated from Gordonia from the intestinal tract of Periplaneta americana for the first time. These indicated that Gordonia rare actinomycetes possessed a potential as a resource of active secondary metabolites.

Material And Methods

Microorganisms

The Gordonia Strain WA 4-31 (MH613773) was isolated from the intestinal tract of Periplaneta americana and deposited in Guangdong Microbial Culture Collection Center (GDMCC NO.1.2521). The tested strain including four kinds of pathogenic fungi: Candida albicans ATCC 10231, Trichophyton rubrum ATCC 60836, Aspergillus niger ATCC 16404, Aspergillus fumigatus ATCC 96918, and four kinds of pathogenic bacteria: methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300, Staphylococcus aureus ATCC 25923, Escherichia coli ATCC 25922 and Pneumobacillus ATCC 13883, were obtained from Guangdong Institute of Microbiology. CNE-2 Human nasopharyngeal carcinoma cell line, HepG2 human hepatocellular carcinoma cells were purchased from Experimental Animal Center of Sun Yat-sen University and Shanghai Cell Biology Institutes respectively.

Media and Chemicals

Microbiological media were purchased from Guangdong Huankai Microbial Co. The genomic DNA isolation kit was purchased from TIANGEN Biotech. High-performance liquid chromatography (HPLC) grade methanol was purchased from ThermoFisher. Silica gel used for extraction and column chromatography were obtained from Qingdao Ocean Chemical Co. Sephadex LH-20 dextran gel, CHP20P MCI and DIASOGEL ODS were purchased from Mitsubishi Chemical Co. of Japan. Solvents used for extraction and column were of analytical grade which were obtained from Guangdong Guanghua Sci-Tech Co.

Identification of Gordonia Strain WA 4-31

The Gordonia strain WA 4-3 was inoculated on Gauze's No. 1 medium and incubate at 28°C for 3 days. Three days later, the single colony was selected and cultivated in the ISP-1 seed medium at 28°C for 2 days. The morphology and surface characteristics of the bacterial colonies were examined using a scanning electron microscope (Hitachi S-3400N, Japan). Whole genomic DNA of the strain was extracted according to the manufacturer's instructions of the genomic DNA isolation kit. The 16S rDNA gene was then amplified by PCR, using universal bacterial primer (27F: 5'-AGA GTT TGA TCC TGG CTC AG-3' and 1492R: 5'-TAC GGC TAC CTT GTT ACGACT T-3'). PCR products were visualized by electrophoresis and was sequenced in BGI. The resulting sequence was compared to all sequences available in GenBank using the BLAST software from the National Center for Biotechnology Information (NCBI) website (http://www.ncbi.nlm.nih.gov/). The phylogenetic tree was constructed by MEGA.

Production and Isolation of Secondary Metabolites from Strain WA 4-31
The ISP 2 medium was used as the production culture. A 9 mL portion of the seed culture was transferred into a
500-mL Erlenmeyer flask containing 300 mL of the ISP 2 medium and incubated on rotary shakers (160 rpm) at
28°C for 21 days. The total 63L of culture broth was extracted 3 times with an equivalent volume of ethyl acetate.
After extraction and evaporation, 13.4g crude ethyl acetate extract was obtained. The crude ethyl acetate of the
strain WA 4-31 was separated to given 20 major fractions (1-20) using silica gel. The crude extract and every
fraction were tested for antimicrobial activity against *Candida albicans* ATCC 10231 by Oxford Cup method.
Finally, the active fractions were further purified by ODS column chromatography, Sephadex LH-20 column, and
high-performance liquid chromatography (HPLC) to offer compounds.

**Spectroscopic Analysis**

The molecular weight of the purified compounds was determined using mass spectrometry and their structure was
characterized by 1H NMR and 13C NMR. The compounds were fully dissolved in methanol with a concentration of
about 1 mg/L, filtered with a 0.22 μm filter membrane, and then mass spectra was obtained within the range of
m/z 100-1500 by TSQ Endura™ Triple-quadrupole mass spectrometer (Thermo Scientific, USA). Selecting
appropriate 600μL of deuterated reagent to dissolve 10.0 mg of the compounds, the proton and carbon nuclear
magnetic resonance (NMR) spectra were recorded at 600 MHz using a Brucker AVANCE III 600M spectrometer
(Brucker, Germany).

**Determination of minimum inhibitory concentration (MIC)**

Minimum inhibitory concentration (MIC) measurements of compounds against the tested strain were performed by
a microdilution method. The compounds were dissolved in DMSO and then diluted by the twofold dilution
method. 100 μL bacterial suspension or fungi suspension (10⁶ CFU/mL) were added to the 96-well plates.
Then 100 μL compounds were added to the 96-well plates respectively. The final concentrations of each sample in
the wells were 512, 256, 128, 64, 32, 16, 8, 4, 2, 1, 0.5 and 0.25 μg/mL. Amphotericin B, Vancomycin, Ampicillin and
Ciprofloxacin were used as positive drugs for fungi, MRSA, *Pneumococcus* and *Escherichia coli* respectively. The
MIC value of the compounds was determined as the lowest concentration that completely inhibited bacterial
growth after 48 h of incubation at 37°C, while the fungi was incubated at 28°C. All experiments were performed in
triplicate.

**Filter paper diffusion method**

Antifungal activity against *Candida albicans* was tested using the filter paper diffusion method. Sterile filter paper
discs (6mm) were taken, soaked sufficiently in different samples for 5 min and set aside. Fungi suspension was
dipped with sterile cotton, and uniformly applied in the culture media. Fully soaked filter paper was placed in the *C.
albicans* containing plates and cultured for 24 h at 28°C. Amphotericin B (32 μg/mL) was used as positive
control. The experiment was performed in triplicate and the mean of the diameter of the inhibition zones was
calculated.

**Cells viability assay**

Cellular viability was evaluated with the MTT (Amresco, USA) assay. 5×10³ cells suspended in 100 μl DMEM
medium were added into a 96-well plate and treated with different concentrations of compounds for 24 h /48 h /72
h. After then, 10 μL of 0.5 mg/mL MTT reagent was added to each well for an additional 4 h. The purple formazan
crystals were dissolved with 100 μL DMSO per well for further quantitative measurement at an absorbance of 570 nm using a microplate spectrophotometer. Experiments were independently repeated three times.

**Results**

**Identification of the strain WA 4-31**

The colonies of strain WA 4-31 on Gauze's medium were milky yellow. The surface of the colony was smooth and moist, and its edge was irregularly convex (Fig. 1 (A)). The strain WA 4-31 was observed to be short rod-shaped and unbranched under electron microscope (Fig. 1 (B) (C)). The sequence of this strain WA 4-31 was submitted to GenBank of NCBI, and the accession number was MH613773. The strain WA 4-31 of the 16S rRNA gene sequence was compared by BLAST and homologous to *Gordonia* from a cold desert of the Indian (EU333873) by 100% (Fig. 1 (E)), the deposit number was GDMCC NO.1.2521.

**Isolation of Secondary Metabolites**

The crude ethyl acetate extract (about 13.4 g) was firstly separated by silica gel column chromatography eluting with a gradient system of CHCl₃:CH₃COOC₂H₅ and CH₃COOC₂H₅:CH₃OH to yield 20 fractions. Six fractions showed activity against *Candida albicans* ATCC 10231 by Oxford Cup method, especially the 10th fraction was strongest, the diameters of inhibition zones of which was 36.0±2.0 mm, while the others did not show activity (Fig.2, Table 1). These fractions with anti-*Candida albicans* activity were repeatedly purified by silica gel column, ODS column, Sephadex LH-20 column and HPLC to offer compound 1 (7.7 mg), compound 2 (24.2mg), compound 3 (34.1 mg) and compound 4 (35.9 mg).

**Identification of Compounds**

Compound 1, orange powder; HR-ESI-MS m/z 1255.46 [M+H] +, m/z 1277.39 [M+Na] +. Compound 2, orange powder; HR-ESI-MS m/z 1269.42[M+H] +, m/z 1291.44 [M+Na] +. Compound 3, white solid; HR-ESI-MS m/z 1086.51[2M+H] +, m/z 1107.43 [M+Na] +. Compound 4, colorless needle-like solid; HR-ESI-MS m/z 227.15 [M+H] +. The chemical structure of compounds 1-4 was identified based on the spectral information relating to ¹H NMR and ¹³C NMR spectral data (See Supplementary), which were respectively confirmed to be Actinomycin D (1), Actinomycin X₂ (2), Mojavensin A (3) and cyclic (leucine-leucine) dipeptide (4) by comparing the microspectrum, SciFinder and related references (Fig. 3).

**Antimicrobial activity of Compounds**

The MIC experiment found that compounds 1-4 have broad spectrum antimicrobial activity (Table 2), especially compound 3 Mojavensin A had the best effect on the four kinds of the tested fungi: *Candida albicans*, *Trichophyton rubrum*, *Aspergillus fumigatus* and *Aspergillus niger*. Compound 4 (leucine) -Leucine) dipeptide has the strongest inhibitory effect on *E. coli* at 32 μg/mL. In addition, compounds 1 Actinomycin D and compounds 2 Actinomycin X₂ have the best effects against MRSA (ATCC 43300), with an inhibitory effect of 0.25 μg/mL.

Interestingly, Mojavensin A and cyclic (leucine-leucine) dipeptide which were separated from the tenth fraction with the strong activity against *Candida albicans* (Fig.4), mixed with different proportions had stronger activity against *Candida albicans* than every single compound. When the ratio was 1:1, the activity against *Candida albicans* was the strongest, but it still did not reach the strength of the tenth fraction (Table 3).
Antiproliferative activity of Compounds

Cytotoxicity of Compounds 1-3 Actinomycin D, Actinomycin X_2_ and Mojavensin A for HepG-2 and CNE-2 cells was performed by MTT at different time. Results show that compounds 1-3 could inhibited cell proliferation in a time-dependent manner(Fig.5). Meanwhile the inhibitory effect of them for HepG-2 had the concentration correlation. The antiproliferative effect of Actinomycin D and Actinomycin X_2_ was more effectively than Mojavensin A at the Concentration of less than 50 μg/ml. According to the inhibition rate of different concentrations, the half-maximal inhibitory concentration (IC50) of the compounds on HepG-2 and CNE-2 cells were calculated using the probability distribution of SPSS13.0 (Table 4).

Discussion

The growing resistance of microorganisms towards antibiotics has become a serious problem around the world. Therapeutics with novel chemical scaffolds and/or mechanisms of action are urgently needed to combat infections caused by multidrug resistant pathogens, including bacteria, fungi and viruses. Development of novel antimicrobial agents still highly depends on the new natural products. At present, most antimicrobial drugs used in medicine are of natural origin. Among the natural producers of bioactive substances, actinobacteria continue to be an important source of novel secondary metabolites for drug application (Jakubiec-Krzesniak K et al. 2018). It was estimated that from the first report of streptothricin in 1942 and streptomycin a year later, the order Actinomycetales had yielded about 3000 known antibiotics (Clardy J et al. 2006). However, with the known antibiotics are discovered repeatedly, there are fewer new antibiotics found from Streptomyces. Rare actinomycetes have been paid more attention as the hope of discovering new antibiotics. Ramesh et al. reported that 167 new bioactive compounds produced by 58 different rare actinomycete species representing 24 genera. A total of 97 new species, representing 9 novel genera and belonging to 27 families of marine rare actinomycetes had been reported from mid-2013 to 2017(Subramani R and Sipkema D 2019). About 20 years ago, rare actinomycete Gordonia was described as a genus, and there are 39 different species have been identified so far (Sowani H et al. 2018). Some Gordonia species cause a broad spectrum of diseases in healthy and immunocompromised individuals. Besides, these bacteria can produce useful secondary metabolites that may be used in various industries (Nahurira R et al. 2019).

In this study, we validated the endogenous Gordonia isolated from the intestinal tract of Periplaneta americana by sequence and phylogenetic tree construction and we named this Gordonia strain WA 4-31. Phylogenetic data showed that the strain WA 4-31 was 100% homologous to Gordonia from the Indian desert. Colony conformed to the biomarker of Gordonia by colony phenotype. Previous studies have shown that the endogenous environment of insects is unique and the natural products form the endogenous environment of insects may be different from the common environment in the land. Therefore, it is speculated that insect endobacteria may produce precious and interesting natural compounds (Beemelmanns C. et al. 2016; Newman D.J. and Cragg G.M. 2016; Chevrette MG et al. 2019). Insects are a highly diverse group, exploit a wide range of habitats, and harbor bacterial symbionts of largely unknown diversity. Insect-associated bacterial symbionts are underexplored but promising sources of bioactive compounds (Martinez AFC et al. 2019). Lee SR et al.(2018) reported the discovery of three new cyclic tripeptides: natalenamides A-C. These compounds were identified from the culture broth of the fungus-growing termite-associated Actinomadura sp. RB99. Li TX et al.(2020) reported two new compounds, versicolones A and B and three known pyrone derivatives were isolated from the insect-associated fungus Aspergillus versicolor. At the present study, four antimicrobial compounds were isolated from the secondary metabolite of the strain WA4-31.
Although these compounds, Actinomycin D, Actinomycin X2 and Mojavensin A were reported, which found in *Gordonia* is the first time. There was no report that they were found in secondary metabolites at the same time so far.

In our study, Actinomycin D and Actinomycin X\textsubscript{2} showed extremely strong activity on MRSA, reached 0.25 $\mu$g/mL respectively, which was consistent with the existing reports (Rathod BB et al. 2018; Sharma M and Manhas RK. 2019). These two Actinomycins showed general resistance to the remaining tested pathogens, which was different, compared with some reports. Xiong et al. found that Actinomycin X\textsubscript{2} had strong antibacterial activity against several Gram-positive and Gram-negative bacteria examined (*Staphylococcus aureus*, *Pseudomonas solanacearum*, *Escherichia coli*, etc.) and was especially effective against *S. aureus*, with MIC\textsubscript{50}, 0.002 $\mu$g/ml; MIC\textsubscript{90}, 0.017 $\mu$g/ml (Xiong ZQ et al. 2012). Actinomycin D from the study by Zhang et al. were evaluated for their activity against the growth of methicillin-resistant *S. aureus*, *E. coli*, and *C. albicans* using the micro broth dilution method and the results showed that Actinomycin D significantly inhibited the growth of both bacteria and fungi with MIC values of 0.08 to 9.96 $\mu$M (Zhang XF et al 2016). Among compounds, Mojavensin A had the best inhibitory activity against *Aspergillus niger*, *Trichophyton rubrum* and *Aspergillus fumigatus*, reaching 32 $\mu$g/mL, 16 $\mu$g/mL and 64 $\mu$g/mL. The inhibitory effect of compound 3 Mojavensin A on *Escherichia coli* was 32 $\mu$g/mL. Mojavensin A was found in 2012 for the first time (Ma Z et al. 2012). In another report said mojavensins displayed moderate antagonism and dose-dependent activity against several formae speciales of *Fusarium oxysporum* and presented surface tension activities. These properties demonstrated that these lipopeptides may be useful as biological control agent to fungal plant pathogens (Ma Z and Hu J 2014). These reports provided good evidence for our study on antimicrobial activity in this article.

In addition, we found a more interesting phenomenon. In the process of separating and purifying the secondary metabolites of strain WA 4-31, it was found that one of the fractions showed strong activity against *Candida albicans* (Fig.2; Table 1). Compound 3 Mojavensin A and compound 4 cyclic (leucine-leucine) dipeptide were obtained by further separation and purification from this fraction. The anti-*Candida albicans* activity of these two compounds was determined, and the activity of single compound was not outstanding. Then we mixed these two compounds according to different proportions, and it was found that the activity was obviously improved, but it still did not reach the strength of the fraction (Fig.4; Table 3). Antimicrobial resistance threatens a resurgence of life-threatening bacterial infections and the potential demise of many aspects of modern medicine. In order to delay the problem of antimicrobial resistance, people have extensively studied the synergistic effect of drugs in recent years. Combinations of antibiotics and of antibiotics with non-antibiotic activity-enhancing compounds offer a productive strategy to address the widespread emergence of antibiotic-resistant strains (Tyers M and Wright GD. 2019; Zheng W et al. 2018). As there are still other complex bioactive components in the fractions that have not been separated, the synergistic effect and its mechanism among the specific compounds with strong anti-*Candida albicans* activity have not yet been determined, which needs further study. The inhibitory activities of all compounds on different bacteria and fungi were not consistent, so it was speculated that their coexistence was complementary for the host. Perhaps the host used them to fight against different pathogenic microorganisms to adapt to various living environments. At the same time, it also showed that the diversity and richness of secondary metabolites were conducive to the adaptation of microorganisms to their living environment for microorganisms themselves, which is of great significance (Cheng MM et al. 2020).

Through our work, we identified a rare actinomycete strain WA 4-31 from the intestinal tract of *Periplaneta americana* as *Gordonia*. Four compounds with antimicrobial activity, Actinomycin D, Actinomycin X\textsubscript{2} and
Mojavensin A, were isolated and purified from the secondary metabolites of the strain WA 4-31. We determined their antimicrobial activity and inhibitory effect on the growth of CNE-2 cells and HepG-2 cells. In addition, we found that Mojavensin A and cyclic (leucine-leucine) dipeptide had a synergistic effect after being mixed in different proportions, which could enhance the anti-*Candida albicans* activity. This phenomenon was a good enlightenment for us, maybe we can continue our in-depth study in the follow-up study on antimicrobial activity.

**Declarations**

**Acknowledgment** The authors gratefully acknowledges Ph.D Xiongming Luo for analyzing the results of compounds.

**Authors’ contributions** XJ devised and supervised the experiments. MX, HL, TY and PG participated in the experiments. WL analyzed data. YM, MX wrote the manuscript. All authors read and approved the manuscript.

**Funding** This work was funded by the Public Welfare Research and Capacity Building Project of Guangdong Province (No. 2016A030303059 and No. 2017A020211008) and the Key Projects of Basic Research and Applied Basic Research of Guangdong Province Normal University No. 2018KZDXM041.

**Availability of data and materials** All the data analysed in this study are included in this article.

**Ethics approval and consent to participate** This article does not contain any studies with human participants or vertebrates performed by any of the authors.

**Consent for publication** Not applicable.

**Competing interests** The authors declare that they have no competing interests.

**References**

Abidi S, Achar J, Assao Neino MM, Bang D, Benedetti A, Brode S, Campbell JR, Casas EC, Conradie F, Dravniece G, du Cros P, Falzon D, Jaramillo E, Kuaban C, Lan Z, Lange C, Li PZ, Makhmudova M, Maug AKJ, Menzies D, Migliori GB, Miller A, Myrzaliev B, Ndjeka N, Noeske J, Parpieva N, Piubello A, Schwoebel V, Sikhondze W, Singla R, Souleymane MB, Trébucq A, Van Deun A, Viney K, Weyer K, Zhang BJ, Ahmad Khan F (2020) Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. Eur Respir J. 55(3):1901467. doi: 10.1183/13993003.01467-2019

Beemelmanns C, Guo H, Rischer M, Poulsen M (2016) Natural products from microbes associated with insects. Beilstein J Org Chem.12:314-327. doi:10.3762/bjoc.12.34

Chen Z, Ou P, Liu L, Jin X (2020) Anti-MRSA Activity of Actinomycin X2 and Collismycin A Produced by *Streptomyces globisporus* WA5-2-37 From the Intestinal Tract of American Cockroach (*Periplaneta americana*). Front Microbiol. 11:555. doi:10.3389/fmicb.2020.00555

Cheng MM, Tang XL, Sun YT, Song DY, Cheng YJ, Liu H, Li PL, Li GQ (2020) Biological and Chemical Diversity of Marine Sponge-Derived Microorganisms over the Last Two Decades from 1998 to 2017. Molecules. 25(4):853. doi: 10.3390/molecules25040853
Chevrette MG, Carlson CM, Ortega HE, Thomas C, Ananiev GE, Barns KJ, Book AJ, Cagnazzo J, Carlos C, Flanigan W, Grubbs KJ, Horn HA, Hoffmann FM, Klassen JL, Knack JJ, Lewin GR, McDonald BR, Muller L, Melo WGP, Pinto-Tomás AA, Schmitz A, Wendt-Pienkowski E, Wildman S, Zhao M, Zhang F, Bugni TS, Andes DR, Pupo MT, Currie CR (2019) The antimicrobial potential of *Streptomyces* from insect microbiomes. Nat Commun. 10(1):516. doi: 10.1038/s41467-019-08438-0

Clardy J, Fischbach MA, Walsh CT (2006) New antibiotics from bacterial natural products. Nat Biotechnol. 24(12):1541-1550. doi:10.1038/nbt1266

Dantur KI, Enrique R, Welin B, Castagnaro AP (2015) Isolation of cellulolytic bacteria from the intestine of *Diatraea saccharalis* larvae and evaluation of their capacity to degrade sugarcane biomass. AMB Express. 5:15. doi: 10.1186/s13568-015-0101-z

Durán P, Barra PJ, Jorquera MA, Viscardi S, Fernandez C, Paz C, Mora ML, Bol R (2019) Occurrence of Soil Fungi in Antarctic Pristine Environments. Front Bioeng Biotechnol. 7:28. doi: 10.3389/fbioe.2019.00028

Fang X, Shen J, Wang J, Chen ZL, Lin PB, Chen ZY, Liu LY, Zeng HW, Jin XB (2018) Antifungal activity of 3-acetylbenzamide produced by actinomycete WA23-4-4 from the intestinal tract of *Periplaneta americana*. J Microbiol. 56(7):516-523. doi: 10.1007/s12275-018-7510-z

Guo H, Benndorf R, Leichnitz D, Klassen JL, Vollmers J, Görls H, Steinacker M, Weigel C, Dahse HM, Kaster AK, de Beer ZW, Poulsen M, Beemelmanns C (2017) Isolation, Biosynthesis and Chemical Modifications of Rubterolones A-F: Rare Tropolone Alkaloids from *Actinomadura* sp. 5-2. Chemistry. 23(39):9338-9345. doi: 10.1002/chem.201701005

Jakubiec-Krzesniak K, Rajnisz-Mateusiak A, Guspiel A, Ziemska J, Solecka J (2018) Secondary Metabolites of Actinomycetes and their Antibacterial, Antifungal and Antiviral Properties. Pol J Microbiol. 67(3):259-272. doi:10.21307/pjm-2018-048

Kaur N, Arora DS (2020) Prospecting the antimicrobial and antibiofilm potential of *Chaetomium globosum* an endophytic fungus from *Moringa oleifera*. AMB Express.10(1):206. doi: 10.1186/s13568-020-01143-y

Lee SR, Lee D, Yu JS, Benndorf R, Lee S, Lee DS, Huh J, de Beer ZW, Kim YH, Beemelmanns C, Kang KS, Kim KH (2018) Natalenamides A□C, Cyclic Tripeptides from the Termite-Associated *Actinomadura* sp. RB99. Molecules. 23(11):3003. doi: 10.3390/molecules23113003

Li TX, Meng DD, Wang Y, An JL, Bai JF, Jia XW, Xu CP (2020) Antioxidant coumarin and pyrone derivatives from the insect-associated fungus *Aspergillus Versicolor*. Nat Prod Res. 34(10):1360-1365. doi: 10.1080/14786419.2018.1509334

Ma Z, Hu J (2014) Production and characterization of Iturinic lipopeptides as antifungal agents and biosurfactants produced by a marine *pinctada martensii*-derived *Bacillus mojavensis* B0621A. Appl Biochem Biotechnol. 173(3):705-715. doi:10.1007/s12010-014-0879-1

Ma Z, Wang N, Hu J, Wang S (2012) Isolation and characterization of a new iturinic lipopeptide, mojavensisin A produced by a marine-derived bacterium *Bacillus mojavensis* B0621A. J Antibiot (Tokyo). 65(6):317-322. doi:10.1038/ja.2012.19
Martinez AFC, de Almeida LG, Moraes LAB, Cônsoli FL (2019) Microbial Diversity and Chemical Multiplicity of Culturable, Taxonomically Similar Bacterial Symbionts of the Leaf-Cutting Ant Acromyrmex coronatus. Microb Ecol. 77(4):1067-1081. doi:10.1007/s00248-019-01341-7

Martinez-Klimova E, Rodríguez-Peña K, Sánchez S (2017) Endophytes as sources of antibiotics. Biochem Pharmacol. 134:1-17. doi:10.1016/j.bcp.2016.10.010

Mastan A, Vivek Babu CS, Hiremath C, Srinivas KVNS, Kumar AN, Kumar JK (2020) Treatments with native Coleus forskohlii endophytes improve fitness and secondary metabolite production of some medicinal and aromatic plants. Int Microbiol. 23(2):345-354. doi:10.1007/s10123-019-00108-x

Nahurira R, Wang J, Yan Y, Jia Y, Fan S, Khokhar I, Eltoukhy A (2019) In silico genome analysis reveals the metabolic versatility and biotechnology potential of a halotolerant phthalic acid esters degrading *Gordonia* alkanivorans strain YC-RL2. AMB Express. 9(1):21. doi: 10.1186/s13568-019-0733-5

Newman DJ, Cragg GM (2016) Natural Products as Sources of New Drugs from 1981 to 2014. J Nat Prod. 79(3):629-661. doi:10.1021/acs.jnatprod.5b01055

Rathod BB, Korasapati R, Sripadi P, Reddy Shetty P (2018) Novel actinomycin group compound from newly isolated Streptomyces sp. RAB12: isolation, characterization, and evaluation of antimicrobial potential. Appl Microbiol Biotechnol. 102(3):1241-1250. doi:10.1007/s00253-017-8696-4

Riahi K, Hosni K, Raies A, Oliveira R (2019) Unique secondary metabolites of a *Streptomyces* strain isolated from extreme salty wetland show antioxidant and antibacterial activities. J Appl Microbiol. 127(6):1727-1740. doi:10.1111/jam.14428

Sayed AM, Hassan MHA, Alhadrami HA, Hassan HM, Goodfellow M, Rateb ME (2020) Extreme environments: microbiology leading to specialized metabolites. J Appl Microbiol. 128(3):630-657. doi:10.1111/jam.14386

Sharma M, Manhas RK (2019) Purification and characterization of actinomycins from *Streptomyces* strain M7 active against methicillin resistant *Staphylococcus aureus* and vancomycin resistant *Enterococcus*. BMC Microbiol. 19(1):44. doi:10.1186/s12866-019-1405-y

Shintani M, Sugiyama K, Sakurai T, Yamada K, Kimbara K (2019) Biodegradation of A-fuel oil in soil samples with bacterial mixtures of *Rhodococcus* and *Gordonia* strains under low temperature conditions. J Biosci Bioeng. 127(2):197-200. doi:10.1016/j.jbiosc.2018.07.018

Silva FA, Liotti RG, Boleti APA, Reis ÉM, Passos MBS, Dos Santos EL, Sampaio OM, Januário AH, Branco CLB, Silva GFD, Mendonça EAF, Soares MA (2018) Diversity of cultivable fungal endophytes in Paullinia cupana (Mart.) Ducke and bioactivity of their secondary metabolites. PLoS One. 13(4):e0195874. doi: 10.1371/journal.pone.0195874

Sivalingam P, Hong K, Pote J, Prabakar K (2019) Extreme Environment Streptomyces: Potential Sources for New Antibacterial and Anticancer Drug Leads? Int J Microbiol. 2019:5283948. doi:10.1155/2019/5283948

Sowani H, Kulkarni M, Zinjarde S (2018) An insight into the ecology, diversity and adaptations of *Gordonia* species. Crit Rev Microbiol. 44(4):393-413. doi:10.1080/1040841X.2017.1418286
Table 1 The Inhibition Zone size of the fractions for Candida albicans with Oxford cups method

|                | 3rd fraction | 4th fraction | 10th fraction | 11th fraction | 15th fraction | 16th fraction | Positive drug |
|----------------|--------------|--------------|---------------|---------------|---------------|---------------|---------------|
| Diameter of the inhibition zone (mm) ( n=3, means± SD) | 13.0±1.5 | 10.5±1.0 | 36.0±2.0 | 16.0±1.0 | 13.5±1.0 | 12.0±1.5 | 15.0±1.0 |
| Candida albicans ATCC 10231  |              |              |               |               |               |               | Positive drug |

Table 2 The Minimal inhibitory concentration (MIC) of Compounds against the tested strains (μg/mL)
Table 3 The Inhibition Zone size of various samples against Candida albicans by Filter paper method

| Compound | Candida albicans ATCC 10231 | Trichophyton rubrum ATCC 60836 | Aspergillus niger ATCC 16404 | Aspergillus fumigatus ATCC 96918 | MRSA ATCC43300 | S.aureus ATCC25923 | E.coli ATCC 25922 | K.pneumoniae ATCC 13883 |
|----------|-----------------------------|-------------------------------|-----------------------------|---------------------------------|-----------------|-------------------|-------------------|------------------------|
| Compound 1 | Actinomycin D | Compound 2 | Actinomycin X2 | Compound 3 | Mojavensin A | Compound 4 | cyclic (leucine-leucine) dipeptide |
| Candida albicans ATCC 10231 | 32 | 128 | 64 | >256 | Trichophyton rubrum ATCC 60836 | 128 | 128 | 16 | >256 | Aspergillus niger ATCC 16404 | 128 | 128 | 32 | 128 | Aspergillus fumigatus ATCC 96918 | 128 | 128 | 64 | >256 | MRSA ATCC43300 | 0.25 | 0.25 | >256 | >256 | S.aureus ATCC25923 | 64 | 128 | >256 | >256 | E.coli ATCC 25922 | 64 | 128 | 32 | 32 | K.pneumoniae ATCC 13883 | 64 | 128 | >256 | >256 |

Diameter of the inhibition zone (mm) (n=3, means± SD)

Table 4 The half-maximal inhibitory concentration (IC₅₀) of compounds on HepG-2 and CNE-2 cells for 24-72 h (μg/mL)

| Compound | HepG-2 | CNE-2 |
|----------|--------|--------|
|          | 24h    | 48h    | 72h    | 24h    | 48h    | 72h    |
| Actinomycin D | >200 | 29.74 | 12.16 | >200 | 15.02 | 1.24 |
| Actinomycin X₂ | >200 | 14.68 | 5.37 | >200 | 84.38 | 0.93 |
| Mojavensin A | - | >200 | >200 | >200 | 130.72 | 51.03 |

Figures
Figure 1

Results of strain identification (a) Colonies of Strain WA4-31 on Gauze's medium. (b) Observation Results of Strain WA4-31 under Scanning Electron Microscope of 5000×. (c) Observation Results of Strain WA4-31 under Scanning Electron Microscope of 20000×. (d) Detection of PCR Products of 16S rDNA by Agarose Gel Electrophoresis. 1: Black control; 3: WA4-31 16S rDNA; 5: 2000 DNA marker. (e) Phylogenetic Tree of Strain WA 4-31. Maximum-likelihood phylogenetic tree based on 16S rDNA gene sequences showing the positions of strain WA 4-31, the type strains of other Gordonia and representatives of some other related taxa. Only bootstrap values (expressed as percentages of 1,000 replications) greater than 50% are shown at branching points. Bar, 0.02 substitutions per nucleotide position.

Figure 2

The antibacterial activity of different fractions against Candida albicans with Oxford Cup method (a) The 3rd and the 4th fractions had anti-Candida albicans activity, (b) while the 5th and the 6th did not, (c) The 10th fraction had stronger antibacterial activity. 1: Positive drug: Amphotericin B, 32 μg/mL; 2: Blank control: methanol solution; 3-7: Methanol solutions with different fractions, 5mg/mL.
Figure 3

Molecular Structure of compound 1-4 (a) compound 1: Actinomycin D. (b) compound 2: Actinomycin X2. (c) compound 3: Mojavensin A. (d) compound 4: cyclic (leucine-leucine) dipeptide

Figure 4

Activity of various samples against Candida albicans by Filter paper method 1: Positive drug: Amphotericin B, 32 μg/mL; 2: Blank control: methanol solution; 3: the tenth fraction dissolved in methanol, 1mg/mL; 4: Mojavensin A dipeptide dissolved in methanol, 512 μg/mL; 5: Cyclic (leucine-leucine) dipeptide dissolved in methanol, 512 μg/mL; 6: Mojavensin A: cyclic (leucine-leucine) dipeptide =2: 1; 7: Mojavensin A: cyclic (leucine-leucine) dipeptide =1: 1; 8: Mojavensin A: cyclic (leucine-leucine) dipeptide =1: 2.
Figure 5

The cytotoxicity (MTT ASSAY) results of compounds on HepG-2 cells (a) and CNE-2 cells (b) at the different concentrations for 24-72 h.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryFigures.docx
- SupplementaryTables.docx